<DOC>
	<DOC>NCT01319695</DOC>
	<brief_summary>The use of corifollitropin alfa is superior in terms of pregnancy outcome parameters as compared to recombinant follicle stimulating hormone (FSH) during ovarian stimulation protocols in women undergoing in vitro fertilisation.</brief_summary>
	<brief_title>Corifollitropin Alfa Versus Recombinant Follicle Stimulating Hormone (FSH) in Ovarian Stimulation of Women Undergoing in Vitro Fertilisation</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Follicle Stimulating Hormone</mesh_term>
	<criteria>Women aged 1836 years old with a body weight of more than 60 kg up to 90 kg BMI of 1832 kg/m2 Menstrual cycle length of 2335 days An indication for controlled ovarian stimulation for IVF or ICSI history of an endocrine abnormality abnormal outcome of blood biochemistry or hematology abnormal cervical smear chronic disease uterine pathology that interfering with the COS treatment (e.g. fibroids â‰¥ 5 cm)</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>36 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>corifollitropin alfa</keyword>
	<keyword>FSH ovarian stimulation</keyword>
	<keyword>IVF</keyword>
</DOC>